Skip Navigation



Brain Advance Access published online on September 26, 2008

Brain, doi:10.1093/brain/awn233
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
131/11/3034    most recent
awn233v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fassunke, J.
Right arrow Articles by Becker, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fassunke, J.
Right arrow Articles by Becker, A. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Array analysis of epilepsy-associated gangliogliomas reveals expression patterns related to aberrant development of neuronal precursors

Jana Fassunke1, Michael Majores1,2, Achim Tresch3, Pitt Niehusmann1,4, Alexander Grote5, Susanne Schoch1 and Albert J. Becker1

1Department of Neuropathology, 2Department of Pathology, University of Bonn Medical Center, Bonn, 3Gene Center, Ludwig-Maximilians-University, Munich, 4Department of Epileptology and 5Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany

Correspondence to: Albert J. Becker, MD, Department of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany E-mail: albert_becker{at}uni-bonn.de

Gangliogliomas, the most frequent neoplasms in patients with pharmacoresistant focal epilepsies, are characterized by histological combinations of glial and dysplastic neuronal elements, a highly differentiated phenotype and rare gene mutations. Their molecular basis and relationship to other low-grade brain tumours are not completely understood. Systematic investigations of altered gene expression in gangliogliomas have been hampered by their cellular complexity, the lack of suitable control tissue and of sensitive expression profiling approaches. Here, we have used discrete microdissected ganglioglioma and adjacent control brain tissue obtained from the neurosurgical access to the tumour of identical patients (n = 6) carefully matched for equivalent glial and neuronal elements in an amount sufficient for oligonucleotide microarray hybridization without repetitive amplification. Multivariate statistical analysis identified a rich profile of genes with altered expression in gangliogliomas. Many differentially expressed transcripts related to intra- and intercellular signalling including protein kinase C and its target NELL2 in identical ganglioglioma cell components as determined by real-time quantitative RT–PCR (qRT–PCR) and in situ hybridization. We observed the LIM-domain-binding 2 (LDB2) transcript, critical for brain development during embryogenesis, as one of the strongest reduced mRNAs in gangliogliomas. Subsequent qRT–PCR in dysembryoplastic neuroepithelial tumours (n = 7) revealed partial expression similarities as well as marked differences from gangliogliomas. The demonstrated gene expression profile differentiates gangliogliomas from other low-grade primary brain tumours. shRNA-mediated silencing of LDB2 resulted in substantially aberrant dendritic arborization in cultured developing primary hippocampal neurons. The present data characterize novel molecular mechanisms operating in gangliogliomas that contribute to the development of dysplastic neurons and an aberrant neuronal network.

Key Words: glioneuronal; development; migration; network; epilepsy; dysplastic

Abbreviations: ARF3, ADP-ribosylation factor 3; DNETs, dysembryoplastic neuroepithelial tumours; GFP, green fluorescent protein; HSJ2, heat shock 40 kDa protein 4; LDB2, LIM-domain-binding 2; LMO4, LIM domain only 4; MMP2, matrix metallopeptidase 2; NGFR, nerve growth factor receptor; PRKCB1, protein kinase C β-1; ST6GalNAc4, {alpha}-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3-N-acetyl-galactosaminide {alpha}-2,6-sialyltransferase; TRIB1, tribbles homolog 1

Received February 7, 2008. Revised August 19, 2008. Accepted August 20, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.